Number of patients | 12 |
---|---|
Age | Median |
50–74 | 64 |
PS | |
0 | 4 (33%) |
1 | 8 (67%) |
Receptor status | |
ER+ | 12 (100%) |
HER2+ | 3 (25%) |
Adjuvant therapy | |
chemotherapy | 7 (58%) |
endocrine | 7 (58%) |
Primary disseminated disease | 1 (8%) |
Prior chemo regimens for metastatic disease | |
2 | 2 (17%) |
3 | 6 (50%) |
4 | 4 (33%) |
Metastatic sites | |
Lymph nodes | 5 (42%) |
Bone | 10 (83%) |
Lung | 6 (50%) |
Pleura | 5 (42%) |
Liver | 8 (67%) |
Skin | 1 (8%) |
Ipsilateral breast | 2 (17%) |